As Congress considers a variety of proposals to address prescription drug prices, there is a growing trend of states capping the out of pocket costs for insulin. CHIR’s Megan Houston considers the impact of insulin copay caps and how states are limited in their efforts to tackle prescription drug prices.
State legislative sessions are typically a flurry of health policy activity. In recent years, state lawmakers have taken action to stabilize their insurance markets and increase access to coverage. But like so many other constants we have come to rely on, state legislative sessions took a hit this year from the novel coronavirus pandemic, putting current and future state policy initiatives in jeopardy.
Lowering the cost of prescription medication has broad support over the political spectrum and there were many campaign promises to reduce prices. But to date, there’s been little federal action. States, however, are taking the lead with policies designed to protect consumers with chronic conditions from high out-of-pocket costs associated with expensive specialty drugs. A new CHIR brief details the findings from a 50-state survey of such policies and observations from supplementary interviews with state regulators, insurance company representatives and consumer advocates.
The opinions expressed here are solely those of the individual blog post authors and do not represent the views of Georgetown University, the Center on Health Insurance Reforms, any organization that the author is affiliated with, or the opinions of any other author who publishes on this blog.
